The use of Zymosan A and bacteria anchored to tumor cells for effective cancer immunotherapy: B16-F10 murine melanoma model
Authors:
- 1 October 2016
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 39, 295-306
Abstract
No abstract availableKeywords
Funding Information
- Research Support Foundation
This publication has 38 references indexed in Scilit:
- The Use of Anchored Agonists of Phagocytic Receptors for Cancer Immunotherapy: B16-F10 Murine Melanoma ModelPLOS ONE, 2014
- Anticancer TLR agonists on the ropesNature Reviews Drug Discovery, 2012
- Toll-like receptors and cancerNature Reviews Cancer, 2008
- Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonistsNature Medicine, 2007
- Cooperation of Toll-like receptor signals in innate immune defenceNature Reviews Immunology, 2007
- Capillary isoelectric focusing of proteins and microorganisms in dynamically modified fused silica with UV detectionJournal of Chromatography B, 2006
- A novel glyco-conjugate vaccine against fungal pathogensJournal of Experimental Medicine, 2005
- Rapid Protein Anchoring into the Membranes of Mammalian Cells Using Oleyl Chain and Poly(ethylene glycol) DerivativesBiotechnology Progress, 2004
- Rapid covalent coupling of proteins to cell surfaces: Immunological characterization of viable protein-cell conjugatesJournal of Immunological Methods, 1984
- THE TREATMENT OF MALIGNAT TUMORS BY REPEATED INOCULATIONS OF ERYSIPELASThe American Journal of the Medical Sciences, 1893